Assessment of adjuvant chemotherapy benefits after complete mesocolic excision in patients with colon cancer: reanalysis of data from ESCME trial

Chao Wang,Lin Gan,Zhanlong Shen,Kewei Jiang,Zhidong Gao,Yingjiang Ye
DOI: https://doi.org/10.1111/codi.16226
IF: 3.4
2022-06-21
Colorectal Disease
Abstract:Aim The benefits of adjuvant chemotherapy (AC) in colon cancer after complete mesocolic excision (CME) have not been evaluated sufficiently. We reanalyzed the ESCME trial data to investigate the survival benefits and establish AC stratified indications. Methods The data of stage II and III colon cancer patients who received CME in the ESCME trial were reanalyzed. Patients were divided into AC and non‐AC (NAC) groups. The primary outcomes measured were differences in 5‐year cancer‐specific survival (CSS) and disease‐free survival (DFS) between the groups. Results Of the 206 patients enrolled in the study, 125 patients (AC, 49; NAC, 76) had Stage II cancer and 111 (AC, 86; NAC, 25) had stage III cancer. There were no significant differences in the adjusted 5‐year CSS and DFS between the AC and NAC groups. Poor differentiation (hazard ratio (HR), 2.947; 95% confidence interval (CI), 1.218–7.131) and RAS mutation (HR, 3.140; 95% CI, 1.363–7.234) affected the 5‐year DFS significantly in multivariate Cox regression analysis for stage II and III cancer, respectively. In subgroup analysis, AC significantly improved 5‐year DFS (HR, 0.369; 95% CI, 0.140–0.978) for stage III cancer with lymphovascular/perineural invasion compared to NAC. Conclusion The current indication and benefits of AC for colon cancer patients after CME should be reevaluated. AC is more appropriate for stage III cancer with lymphovascular/perineural invasion.
gastroenterology & hepatology,surgery
What problem does this paper attempt to address?